Please use this identifier to cite or link to this item:
Título : Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration
Autor : Pérez Lloret, Santiago 
Peralta, María Cecilia 
Barrantes, Francisco José 
Fecha de publicación : 2016
Editorial : Taylor & Francis
Cita : Pérez Lloret, S., Peralta, M.C., Barrantes, F.J. Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration [en línea]. Expert Opinion on Pharmacotherapy. 2016, 17(18) doi:10.1080/14656566.2016.1254189 Disponible en:
Resumen : Abstract: Dopamine depletion is one of the most important features of Parkinson's Disease (PD). However, insufficient response to dopaminergic replacement therapy suggests the involvement of other neurotransmitter systems in the pathophysiology of PD. Cholinergic degeneration contributes to gait impairments, cognitive impairment, psychosis, and REM-sleep disturbances, among other symptoms. Areas covered: In this review, we explore the idea that enhancing cholinergic tone by pharmacological or neurosurgical procedures could be a first-line therapeutic strategy for the treatment of symptoms derived from cholinergic degeneration in PD. Expert opinion: Rivastigmine, a drug that increases cholinergic tone by inhibiting the enzyme cholinesterase, is effective for dementia, whereas the use of Donepezil is still in the realm of investigation. Interesting results suggest the efficacy of these drugs in the treatment of gait dysfunction. Evidence on the clinical effects of these drugs for psychosis and REM-sleep disturbances is still weak. Stimulation of the pedunculo-pontine tegmental nuclei (which provide cholinergic innervation to the brain stem and subcortical nuclei) has also been used with some success for the treatment of gait dysfunction. Anticholinergic drugs should be used with caution in PD, as they may aggravate cholinergic symptoms. Notwithstanding, in some patients they might help control parkinsonian motor symptoms.
ISSN : 1465-6566
1744-7666 (online)
Disciplina: MEDICINA
DOI: 10.1080/14656566.2016.1254189
Derechos: info:eu-repo/semantics/closedAccess
Appears in Collections:Artículos

Files in This Item:
File Description SizeFormat Existent users please Login
pharmacotherapies-for-parkinson.pdf1,08 MBAdobe PDF    Request a copy
thumb.pdf160,41 kBAdobe PDFThumbnail
Show full item record

Page view(s)

checked on Dec 2, 2023


checked on Dec 2, 2023

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons